Attainment of EULAR/ERA-EDTA treatment targets in the first year in lupus nephritis: A multicenter observational study (EULAR 2023) - Apr 2, 2023 - Abstract #POS1152; Pres time: Jun 2, 2023; 09:30 AM - 10:30 AM; Location: Poster View; "Background The approval of two new drugs, belimumab and voclosporin, in lupus nephritis (LN) over the last years has raised questions regarding their place in the therapeutic algorithm of LN...With SoC therapy [initial therapy: 48.1% cyclophosphamide (CYC), 32.4% mycophenolic acid (MPA), followed by maintenance therapy], 76.7%, 82.6% and 71.1% achieved EULAR/ERA-EDTA renal response rates at 3, 6 and 12 months, respectively...All patients received IV methylprednisolone at baseline [median (IQR) 2.0 (3.0) gr]...Moreover, prednisone doses used in LN tend to be higher than those recommended by EULAR/ERA-EDTA. Predictive factors associated with suboptimal response can help to shape therapeutic decisions identify patients that may benefit from early use of novel therapies."
Clinical • Observational data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|
|
M. Pappa 1; M. Kosmetatou2; A. Pieta3; M. Nikoloudaki4; E. Argyriou5; C. Tsalapaki6; A. Chalkia7; T. Dimitroulas8; M. Cheila9; C. Papagoras10; A. Goules11; D. Petras7; D. Vassilopoulos6; K. A. Boki5; P. Sfikakis1; P. Voulgari12; G. Bertsias4; D. Boumpas2; M. Tektonidou1; A. Fanouriakis1
|